ArticleBlood cancer journal2016

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.

V Stefoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.